COMMUNIQUÉS West-GlobeNewswire

Achieve Life Sciences Names Dr. Mark Rubinstein Interim Chief Medical Officer
11/09/2025
SEATTLE and VANCOUVER, British Columbia, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and [...]
InnovAge Named as One of the Nation’s Best Workplaces in Aging Services™ by Fortune® and Great Place to Work®
11/09/2025
A Leading Provider of PACE, Ranked in Top Tier of 2025 Best in Aging Services Category DENVER, Sept. 11, 2025 (GLOBE NEWSWIRE) -- InnovAge (NASDAQ: INNV), a leading provider of Program of All-Inclusive Care for the [...]
RESTEM to Host R&D Day Highlighting its Next-Generation Immunomodulatory Treatment for Autoimmune and Inflammatory Diseases
11/09/2025
Leading KOLs to discuss the unmet needs and current treatment landscapes of idiopathic inflammatory myopathy (IIM), ulcerative colitis (UC), rheumatoid arthritis (RA), and facioscapulohumeral muscular dystrophy (FSHD) [...]
Faraday Pharmaceuticals to Participate in Upcoming Investor Events
11/09/2025
Topline data from pivotal Phase 3 Iocyte AMI-3 trial expected in Q4 2025 SEATTLE, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Faraday Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on preventing heart [...]
Ipsen - Août 2025 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
11/09/2025
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (conformément à l’article L.233-8 II du Code de commerce et à l’article 223-16 du Règlement Général de l’ [...]
Ipsen - August 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital
11/09/2025
Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation [...]
OSE Immunotherapeutics et la Fondation FoRT annoncent la fin du recrutement dans Combi-TED, l’étude clinique de Phase 2 évaluant Tedopi® en combinaison avec nivolumab ou docétaxel dans le cancer du poumon non à petites cellules
11/09/2025
OSE Immunotherapeutics et la Fondation FoRT annoncent la fin du recrutement dans Combi-TED, l’étude clinique de Phase 2 évaluant Tedopi® en combinaison avec nivolumab ou docétaxel dans le cancer du poumon non à petites [...]
OSE Immunotherapeutics and the FoRT Foundation Announce Completion of Enrollment in Combi-TED, a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Nivolumab or Docetaxel in Patients with Non-Small Cell Cancer
11/09/2025
OSE Immunotherapeutics and the FoRT Foundation Announce Completion of Enrollment in Combi-TED, a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Nivolumab or Docetaxel in Patients with Non-Small Cell [...]
EssilorLuxottica: Nombre total de droits de vote et d’actions composant le capital social au 31 août 2025
11/09/2025
Nombre total de droits de vote et d’actions composant le capital social au 31 août 2025 (Conformément à l’article L.233-8 II du Code de Commerce et aux articles 221-1 et 223-16 du Règlement Général de l’AMF) Paris, [...]
EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of August 31, 2025
11/09/2025
Disclosure of Share Capital and Voting Rights Outstanding as of August 31, 2025 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des [...]
Guidance for the 2025/26 financial year
11/09/2025
ANNOUNCEMENT NO. 291 11 September 2025 Guidance for the 2025/26 financial year ChemoMetec today approved the annual report for 2024/25, including the guidance for 2025/26, which is considered inside information. For [...]
Annual Report 2024/25 - Growing revenue and EBITDA
11/09/2025
ANNOUNCEMENT NO. 292 11 September 2025 Annual Report 2024/25 (1 July 2024 - 30 June 2025) Growing revenue and EBITDA ChemoMetec’s revenue grew by 22% to DKK 495.6 million in 2024/25, and operating profit (EBITDA) [...]
Aesthetic Room Opens New Aesthetic Medicine Center in South Tyrol (Alto Adige) Near Merano and Bolzano
11/09/2025
Algund/Lagundo, South Tyrol (Alto Adige), Italy , Sept. 11, 2025 (GLOBE NEWSWIRE) -- Aesthetic Room , a new center for modern, minimally invasive aesthetic medicine , has officially opened in Algund , near Merano and [...]
Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225
11/09/2025
Supports Clinical Development of CLR 121225, Actinium-Labeled Compound for the Treatment of Solid Tumors FLORHAM PARK, N.J. and GARCHING, Germany and MUNICH, Germany, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Cellectar [...]
FibroBiologics Announces Positive IND-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis Treatment
11/09/2025
Pilot studies underway to advance IND-enabling preclinical development HOUSTON, Sept. 11, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270 [...]
Safety Shot Launches BONK Holdings to Build Treasury in $2.5 Billion BONK Ecosystem
11/09/2025
Company Forms New Subsidiary to House Digital Asset Strategy; Executes $5 Million Purchase to Increase BONK Treasury to Over $63 Million SCOTTSDALE, AZ, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT [...]
SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $23.6 Million in Gross Proceeds
11/09/2025
NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for [...]
Intercept Announces Voluntary Withdrawal of OCALIVA® for Primary Biliary Cholangitis (PBC) from the US Market; US Clinical Trials Involving Obeticholic Acid Placed on Clinical Hold
11/09/2025
MORRISTOWN, N.J., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a wholly owned biopharmaceutical subsidiary of Alfasigma S.p.A., today announced its decision to voluntarily withdraw OCALIVA ® ( [...]
Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings
11/09/2025
Presentations collectively highlight pilavapadin’s potential to improve pain management care for patients with diabetic peripheral neuropathic pain (DPNP) Breadth of the data across Phase 2 program to be discussed at [...]

Pages